Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Wed, 19.08.2020
YOC AG
YOC with moderate decline in turnover in H1/2020 - Increase in profitability through VIS.X(R) platformBerlin, 19 August 2020 - Until the outbreak of the corona pandemic, the turnover growth of YOC AG (ISIN DE0005932735) at Group level was around 20 % compared to the previous year. Due to the subsequent reluctance of advertisers in the period March [ … ]
Wed, 19.08.2020
Achiko AG
Achiko Announces Provisional Patent Filing for Novel Low-Cost Saliva Covid-19 Test Kit
Zurich, 19 August 2020
- A provisional patent for the novel DNA aptamer and saliva Covid-19 test kit has been lodged
- Codenamed "Gumnuts", the test is extremely low cost, convenient and easy to use, significantly cheaper than current RNA and antigen-based tes [ … ]
Wed, 19.08.2020
Dexus Finance Pty Limited
Dexus (ASX: DXS)
ASX release
19 August 2020
2020 Annual results - Positioning for the recovery
Dexus today announced that it had achieved Adjusted Funds From Operations (AFFO)[1] and a distribution of 50.3 cents per security for FY20, while advising its intention to deliver a distribution in line with free cash flow in FY21.
Highlights
Net p [ … ]
Tue, 18.08.2020
RWE Aktiengesellschaft
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL
RWE Aktiengesellschaft („RWE") has decided to increase its share capital through partial utilization of its authorized capital under the exclusion of sh [ … ]
Tue, 18.08.2020
CureVac
CureVac Announces Closing of Initial Public Offering
TÜBINGEN, Germany/ BOSTON, USA - August 18, 2020 - CureVac N.V. ("CureVac" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its initial public offering o [ … ]
Tue, 18.08.2020
MorphoSys AG
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
PLANEGG/MUNICH, Germany and WILMINGTON, Del. - August 18, 2020 - MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi(R) (taf [ … ]
Tue, 18.08.2020
Petro Welt Technologies AG
Petro Welt Technologies AG: Revenue and profit indicators in HY1 2020 overperforms the level of the same period of the previous year - but uncertainties remainVienna, August 18, 2020
In the first half of 2020, the Group revenue of Petro Welt Technologies AG amounted to EUR 154.0 million, up by 12.5% compared to EUR 136.9 million in the same period [ … ]
Tue, 18.08.2020
Cadillac Ventures Inc.
TORONTO, ON / ACCESSWIRE / August 18, 2020 / Cadillac Ventures Inc. (TSXV:CDC)(GREY:CADIF) is pleased to announce that it has entered into a letter of intent ("LOI") with Braveheart Resources Inc. (TSXV:BHT)(OTCQB:RIINF) ("Braveheart") for the purchase of a 100% interest in the Thierry Mine Project ("Thierry") near Pickle Lake, Ontario.
Under the [ … ]
Tue, 18.08.2020
DEUTZ AG
Today, DEUTZ has reached agreement on a key issues paper, representing an important milestone in the implementation of its global 'Transform for Growth' efficiency program. The aim of the measures agreed in this context is to further strengthen the Company's competitiveness at a global level whilst protecting the viability of Germany as a company b [ … ]
Tue, 18.08.2020
RWE Aktiengesellschaft
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL
Today, the management board of RWE Aktiengesellschaft („RWE"), with the approval of the supervisory board, resolved on a capital increase against cash c [ … ]